Carter Gould (Cantor Fitzgerald) — Analyst Ratings, Accuracy & Track Record

Q: How accurate are Carter Gould's stock ratings?

About 52% of Carter's ratings were profitable over a one-year hold, with an average return of +23.1% per rating, measured by 13Foresight from historical prices.

Q: How is Carter ranked?

Carter Gould is ranked #1153 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

Analyst Tracker/Carter Gould

CANT

Carter Gould

Cantor Fitzgerald

Wall Street Analyst

★★★☆☆

#1153

on 13Foresight · ranked by our own returns

52%

Success Rate

+23.1%

Average Return

17 of 33 calls profitable · +11.4% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compare To ⓘ

📈 Across the calls we could measure, roughly 52% of Carter Gould's ratings turned a profit when each position was held for 1 year — averaging +23.1% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

39 Buy 23 Hold 0 Sell

Carter's Stock Coverage 28 ratings · 2026-06-20

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	1-Yr Return
GILD Gilead Sciences	Jun 16, 2026	BUY	Strong Buy -4.8% avg upside 66 analysts	$155.00 25.16% Upside	-2.7%
PFE Pfizer	Jun 06, 2026	HOLD	Buy +34.2% avg upside 45 analysts	$27.00 7.05% Upside	-1.6%
LLY Eli Lilly & Co	May 01, 2026	BUY	Strong Buy -10.5% avg upside 47 analysts	$1230.00 11.99% Upside	+14.2%
AMGN Amgen	Apr 30, 2026	HOLD	Buy -11.6% avg upside 57 analysts	$350.00 3.70% Upside	-1.8%
ABBV AbbVie	Apr 29, 2026	BUY	Buy +2.9% avg upside 43 analysts	$240.00 10.90% Upside	+8.5%
REGN Regeneron	Apr 29, 2026	BUY	Strong Buy +26.9% avg upside 57 analysts	$800.00 31.22% Upside	-11.3%
BMY Bristol-Myers Squibb	Apr 08, 2026	HOLD	Buy +9.1% avg upside 42 analysts	$54.00 0.05% Upside	-6.6%
MRK Merck & Company	Mar 29, 2026	HOLD	Strong Buy +10.7% avg upside 43 analysts	$120.00 5.46% Upside	-1.6%
CYTK Cytokinetics	Feb 25, 2026	BUY	Strong Buy +8.9% avg upside 36 analysts	—	+25.6%
VRTX Vertex Pharmaceuticals	Feb 13, 2026	BUY	Strong Buy -2.6% avg upside 61 analysts	$590.00 30.63% Upside	-6.6%
PCVX Vaxcyte	Jun 10, 2025	BUY	Strong Buy +96.1% avg upside 15 analysts	—	+22.1%
TVTX Travere Therapeutics	Nov 29, 2024	HOLD	Strong Buy -16.0% avg upside 22 analysts	—	+88.2%
BIIB Biogen	Nov 29, 2024	HOLD	Strong Buy +25.1% avg upside 51 analysts	—	+13.4%
GOSS Gossamer Bio	Nov 29, 2024	HOLD	Buy +4379.4% avg upside 17 analysts	—	+377.1%
VOR Vor Biopharma	Nov 29, 2024	HOLD	Buy +199.3% avg upside 17 analysts	—	-49.9%
GERN Geron	Nov 08, 2024	BUY	Strong Buy +239.8% avg upside 19 analysts	$9.00 614.30% Upside	-74.8%
ALEC Alector	Nov 07, 2024	BUY	Hold +532.1% avg upside 14 analysts	$12.00 585.67% Upside	-77.3%
NBIX Neurocrine	Oct 31, 2024	BUY	Strong Buy +7.8% avg upside 37 analysts	$160.00 1.12% Upside	+19.1%
BRNS Barinthus Biotherapeutics	Aug 14, 2024	BUY	Strong Buy +551.3% avg upside 5 analysts	$3.00 353.03% Upside	-3.3%
BA Boeing	Jan 11, 2023	HOLD	Strong Buy +14.2% avg upside 36 analysts	$160.00 28.17% Downside	+7.0%
INSM Insmed	Dec 07, 2022	BUY	Strong Buy +82.2% avg upside 36 analysts	$37.00 61.48% Downside	+45.6%
DE:MRK Merck KGaA	Feb 27, 2020	BUY	Buy +2.2% avg upside 32 analysts	$80.08 39.76% Downside	·
INCY Incyte	Jul 31, 2019	HOLD	Buy +1.0% avg upside 47 analysts	$86.00 12.52% Downside	+16.3%
UTHR United Therapeutics	May 17, 2019	HOLD	Buy -18.7% avg upside 26 analysts	$94.00 82.54% Downside	+28.4%
ACIU AC Immune SA	Feb 01, 2019	HOLD	Strong Buy +233.3% avg upside 5 analysts	$4.00 66.59% Upside	+133.4%
RNAC Cartesian Therapeutics	Jan 11, 2019	HOLD	Strong Buy +228.2% avg upside 19 analysts	$2.80 71.02% Downside	+23.0%
BTAI Bioxcel Therapeutics	Nov 12, 2018	BUY	Buy +1918.5% avg upside 12 analysts	$13.00 983.40% Upside	-20.1%
ESPR Esperion	May 16, 2018	BUY	Buy +701.2% avg upside 22 analysts	$75.00 2280.96% Upside	+22.6%

🔒 23 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Carter Gould — Frequently Asked Questions

How accurate are Carter Gould's stock ratings?

Based on the calls 13Foresight could measure, about 52% of Carter's ratings were profitable over a one-year hold, with an average return of +23.1% per rating, or +11.5% versus the S&P 500. We score every analyst the same way, from historical prices.

How is Carter ranked on 13Foresight?

Carter Gould is currently ranked #1153 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Carter cover?

Carter most recently has ratings on GILD, PFE, LLY, AMGN, ABBV, REGN, BMY, MRK, CYTK, VRTX, PCVX, TVTX and 16 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Rating Distribution

Welcome to 13Foresight!